RPL17 and lymphangioleiomyomatosis: Therefore, overexpressed PD-1/PD-L1 in LAM nodules might be molecular targets for checkpoint blockade immunotherapy in LAM patients, and PD-1/PD-L1 blockade monotherapy or combination therapy of rapamycin and PD-1/PD-L1 inhibitors might be promising approaches for LAM.